Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Outstanding Issues

The chemical rational for the adoption of the d haem ring has not been rigorously determined. Nitrite reduction is one of many examples where biology can use copper or iron. It is striking that no organic cofactor is needed for the copper enzyme. [Pg.538]

Averill, B. A., 1996, Dissimilatory nitrite and nitric oxide reductases. Chemical Reviews 96 2951n2964. [Pg.538]

Saunders, N. F. W., Willis, A. C., Ferguson, S. J., Hajdu, J., and F,Fp, V., 1997, Cytochrome cdi structure unusual haem environments in a nitrite reductase and analysis of factors contihuting to P-propeller folds, J. Mol. Biol. 269 4409455. [Pg.538]

Ferguson, S. J., Moir, J. W. B., and Richardson, D. J., 1995, Enzymes and associated electron transport systems that catalyse the respiratory reduction of nitrogen oxides and oxyanions, Biochim. Biophys. Acta 1231 97nl73. [Pg.538]

In this concluding section we summarize our views of the status of some of the current efforts to decipher volatile evolutionary history. This is by no means a comprehensive overview of the field. It concentrates instead on areas that appear to the authors to have the greatest potential for illuminating the general problem. [Pg.235]

Atmospheric Xe inventories in hydrodynamic escape modeling are considered to be [Pg.236]

If this is the case, atmospheric compositions on Venus are enormously important in the context of models for the origin and evolution of terrestrial planet volatiles, particular in the case of Xe. The general similarity of nonradiogenic Xe isotope ratios on Earth and Mars is the strongest argument in favor of the fractionation of Xe on common pre-planetary carriers rather than on the planets themselves, although the correspondence does not appear to be exact. The ability of Venusian Xe to rule between the predictions of [Pg.237]

An equally significant question is whether nonradiogenic Xe on Venus, if solar-like, is compositionally closer to SW-Xe or to U-Xe, or to modestly fractionated derivatives of one or the other. One might expect that Earth and its sister planet would both have acquired their primordial gases from similar source(s) at about the same time, and that the U-Xe required for Earth in the modeling would also have been present in Venus early atmosphere. If it was, the mystery of Mars apparently different primordial Xe composition—SW-Xe or perhaps Cl-Xe—is deepened but if Venusian Xe more closely resembles SW-Xe, then Earth is the modeling anomaly. [Pg.238]

Preparation of this chapter was supported at the University of Minnesota by Grant NAG5-7094 from the NASA Cosmochemistry Program. Reviews by R. Wieler and C. Ballentine are appreciated. [Pg.239]


Protocol. In 1997, prior to President Clinton s acceptance of the Kyoto Protocol, U.S. Senate Resolution 98, the Byrd-Hcgcl resolution, which was passed by a vote of ninety-five to zero, imposes specific requirements that must be met before the Kyoto Protocol can be ratified. The resolution calls for a specific timeline and commitments by developing countries to reduce greenhouse gas emissions, and evidence that adoption of the Kyoto Protocol would not result in serious harm to the U.S. economy. In addition, the Fifth Conference of the Parties (1999) failed to resolve numerous outstanding issues held over from the previous conference, and put off critical decision making until the Sixth Conference of the Parties in The Ffague, Netherlands, in November 2000. [Pg.250]

The review of MRL applications is similar to that for centralised marketing authorisations conducted by the EMEA, in that rapporteurs are responsible for the hands-on evaluation, which is then reported back to the CVMP for consideration. If there are outstanding issues, a list of questions is forwarded to the applicant for his or her response. Otherwise, a formal opinion is prepared and presented to the Commission for legal implementation as a decision. The maximum time allowed to deliver a CVM P opinion is 120 days, excluding the time taken for an initial validation of the application and review of responses form the applicant where necessary. [Pg.138]

In the following sections, an attempt is made to provide a critical outline of experimental aspects of investigations directed to biodegradation and biotransformation, with particular emphasis on outstanding issues to which sufficient attention has not always been paid, and which have not therefore received ultimate resolution. Before proceeding further, it is desirable to define clearly some operational terms ... [Pg.247]

Interpretation of this observed correlation between a lowered affinity of the metal surface to oxygen and a higher rate of ORR measured at a Pt shell over a Pt-alloy core has also been at the center of recent theoretical work, based primarily on DFT calculations of electronic properties and surface bond strengths for a variety of expected ORR intermediates at metal and metal alloy catalysts. The second part of this chapter contains a discussion of these valuable contributions and of outstanding issues in tying together this recent theoretical work and ORR experimental data. [Pg.8]

In the following section, we first review some of the outstanding issues that need to be resolved to better understand intraplate magmatism. We then discuss some of the specific advances that were possible using U-series. Specific features related to magma differentiation and crustal processes are dealt with in the chapter in this volume by Condomines et al. (2003). [Pg.215]

The donor-DNA assemblies presented in Table 2 have been used to probe CT over distinct regimes of time, energetics and coupling. Is it possible to reconcile these many different experiments together within one mechanistic picture Many different theoretical treatments have been proposed, and to greater or lesser extents, these can be used to understand aspects of CT within DNA. However, many outstanding issues remain. Some are highlighted here. [Pg.110]

S.G. Ryan The halo lithium plateau outstanding issues . In This volume. [Pg.178]

Abstract. We examine outstanding issues in the analysis and interpretation of the halo Li plateau. We show that the majority of very Li-poor halo Li-plateau stars (5 out of 8) have high projected rotation velocities usim between 4.7 and 10.4 km s 1. Such stars have very different evolutionary histories to Li-normal plateau stars, and hence cannot be included in studies of Li depletion by normal halo dwarfs. Uncertainties in the effective temperature scale for metal-poor stars continue to challenge the analysis of Li. [Pg.185]

The Conference did not result in a radical change of direction for the OPCW or substantive decisions on crucial, still outstanding issues (e g. so called non-lethal agents, riot control agents, law enforcement , nil declarations in respect of OCPFs and like. The problems of scientific and technological development were tackled only very generally. [Pg.55]

In a review similar to the present one published several years ago (53), we listed the outstanding issues, as we saw them, regarding the action of hallucinogenic drugs. To date, many have remained unanswered, and new ones have now arisen. Therefore, I end this chapter by listing some issues, old and new, that remain unresolved ... [Pg.228]

The approximate treatment described above accounts rather well for the linear rheology of star polymer melts. In fact it has been remarked that the case for the tube model draws its real strength from the results for star polymers rather than for linear chains, where the problems of constraint release and breathing modes are harder to account for (but see Sect. 3.2.4.). However, there are still some outstanding issues and questions ... [Pg.218]

Impressive progress has been made in elucidating molecular mechanisms underlying Tr cell development and differentiated functions. The stage is now set to tackle some important outstanding issues in the field. These include the nature of the molecular circuitry governing the... [Pg.24]

After submission, the rapporteur and corapporteur have 120 days for their review and to write a draft assessment report. The two assessments are then discussed by the parties and a list of outstanding issues are sent to the sponsor at which point the clock is stopped. After the answers have been received, the rapporteur has a further 30 days to finalize the assessment report, which is sent to the CPMP or CVMP. The CPMP/CVMP members also receive a copy of Part 1 of the dossier and may request the full dossier. After a total of 210 days, the CPMP or CVMP delivers an opinion, favorable or unfavorable. [Pg.70]

Despite acknowledged successes, some outstanding issues still exist regarding the actual consequences of exposure to chemicals for humans and the environment, which have become more pressing ... [Pg.30]

For continuous data, there are still a number of outstanding issues regarding the benchmark including (Crump 2002) (1) definition of an adverse effect (2) whether to calculate the BMD from a continuous health outcome, or first convert the continuous response to a binary (yes/no) response (3) quantitative definition of the BMD, in particular in such a manner that BMD from continuous and binary data are commensurate (4) selection of a mathematical dose-response model for calculating a BMD (5) selection of the level of risk to which the BMD corresponds and (6) selection of a statistical methodology for implementing the calculation. [Pg.93]

By day 50, all CMSs are required to have communicated their concerns to the RMS. By day 60, the applicant, with the help of the RMS, responds to all CMSs, addressing their concerns and enclosing an RMS-approved revised SPC. At day 75, outstanding issues of major concerns are discussed in a face-to-face meeting, known as the Breakout Session, between the RMS, CMSs and the applicant. The SPC is still revised further if necessary with the agreement of the RMS. By... [Pg.513]

Crespi, R. (1993). Biotechnological inventions and the patent law outstanding issues. Biotechnol. Genet. Eng. Rev. 11, 229-261. [Pg.90]

Is the equipment to be used newly acquired If so, has it undergone requisite IQ, OQ, and PQ activities If so, how good are the completed packages Before the equipment was received from the vendors, were vendor equipment qualifications (also known as factory acceptance tests—FAT) conducted and were the results satisfactory Are there any outstanding issues requiring resolution Some assumptions will of course be made. These assumptions are listed in Table 5. [Pg.302]

If any subsection of the data documentation (Section 2) is incomplete or if any deviation from the listed acceptance criteria is deemed unacceptable by the signatories, then this document cannot be approved. If it cannot be approved, timely activity closure is recommended and will require that all outstanding issues are resolved to the satisfaction of the quality representative or document termination with a cover note explaining the reasons for the termination. In either case, the parties who approved the unexecuted protocol must approve the resolution and/or the termination. Approval of all protocol explanations is required prior to the approval of a revised protocol generated to accomplish similar objectives. [Pg.315]

Sample Custodians open the coolers, remove the COC Forms and verify the COC Form against the cooler contents. At many laboratories, Sample Custodians will not sign and date the COC Form and log-in a sample into the LIMS until all identified discrepancies have been resolved with the client. The resolution of outstanding issues may delay the start of analysis and erode the sample holding time. The following mistakes made by field sampling personnel are detected at this first step of the laboratory process ... [Pg.189]

As of this writing, there are a number of outstanding issues that remain unresolved and that could threaten the viability of the MRA. One of FDA s biggest concerns is the unharmonized definition of GMP and the EU member states interpretation and enforcement of quality system standards. Another potential problem is the EU s reluctance to conduct inspections of APIs, despite their inclusion in the pharmaceutical GMP annex. [Pg.563]


See other pages where Outstanding Issues is mentioned: [Pg.120]    [Pg.97]    [Pg.392]    [Pg.516]    [Pg.78]    [Pg.110]    [Pg.185]    [Pg.170]    [Pg.228]    [Pg.300]    [Pg.201]    [Pg.586]    [Pg.163]    [Pg.184]    [Pg.109]    [Pg.512]    [Pg.518]    [Pg.520]    [Pg.665]    [Pg.12]    [Pg.541]    [Pg.244]    [Pg.1]    [Pg.164]    [Pg.368]    [Pg.55]    [Pg.146]    [Pg.251]    [Pg.209]   


SEARCH



© 2024 chempedia.info